Nuvectis Pharma, Inc. (NVCT)

Over the past six months, Nuvectis Pharma's stock increased by 54.3% from $7.55 to $11.65, with a 52-week trading range between $5.55 and $11.15. Key events include the company reporting a net loss of $6.1 million in Q1 2026, insider stock buying reaching US$2.07 million, a price target decrease of 11.71% to $16.66, presentations for NXP900 at the 2026 AACR Meeting, initiation of the Phase 1b study of NXP900 in combination with Osimertinib in patients with NSCLC, and hosting a virtual Key Opinion Leader meeting to discuss the NXP900 Phase 1b program. A new minor risk of shareholder dilution was identified in May 2026, with an 18% increase in shares outstanding over the past year.

As a clinical-stage biopharmaceutical company, Nuvectis Pharma, Inc. does not have discernible demand seasonality for its products and services, as its drug candidates are in clinical trials and not yet commercially available. The company's revenue is currently reported as null, and it is not yet profitable.

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology, operating within the Healthcare sector, specifically in Biotechnology and Drug Discovery. The company's pipeline includes NXP800, an oral small molecule GCN2 activator in Phase 1b clinical trials for platinum-resistant, ARID1a-mutated ovarian carcinoma and cholangiocarcinoma, and NXP900, a targeted-therapy small molecule drug candidate that inhibits c-Src (SRC) and YES1 kinases, undergoing a Phase 1a dose escalation study.

Nuvectis Pharma, Inc. is headquartered in Fort Lee, New Jersey, United States.

Nuvectis Pharma's brand reputation is tied to its scientific advancements and clinical trial progress in oncology. Positive updates from clinical trials for NXP800 and NXP900 contribute positively to its scientific and medical reputation. Poster presentations and announcements at scientific meetings help maintain its visibility and credibility. A potential risk to its reputation is the reported shareholder dilution, indicating an 18% increase in shares outstanding.

Nuvectis Pharma, Inc. has a mixed ownership structure with approximately 16.00% held by institutional shareholders, 42.17% by insiders, and 41.83% by retail investors. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and Iridian Asset Management Llc/ct. Ron Bentsur is the largest individual owner with 13.88% of the company, followed by Marlio Charles Mosseri (12.25%) and Enrique Poradosu (6.82%).